# Everolimus, Cytarabine, and Daunorubicin in Treating Patients With Relapsed Acute Myeloid Leukemia

> **NCT00544999** · PHASE1 · UNKNOWN · sponsor: **Institut de Recherche Clinique sur les Cancers et le Sang** · enrollment: 21 (estimated)

## Conditions studied

- Leukemia

## Interventions

- **DRUG:** cytarabine
- **DRUG:** daunorubicin hydrochloride
- **DRUG:** everolimus
- **OTHER:** laboratory biomarker analysis
- **OTHER:** pharmacological study

## Key facts

- **NCT ID:** NCT00544999
- **Lead sponsor:** Institut de Recherche Clinique sur les Cancers et le Sang
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2007-09
- **Primary completion:** 2010-04
- **Final completion:** —
- **Target enrollment:** 21 (ESTIMATED)
- **Last updated:** 2013-09-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00544999

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00544999, "Everolimus, Cytarabine, and Daunorubicin in Treating Patients With Relapsed Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00544999. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*